The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Stocks pull back from five-month high

Wed, 23rd Oct 2013 17:01

- Miners, banks weigh on Footsie- Money-market rates spike in China- RSA up on bid speculationtechMARK 2,624.47 -0.41%FTSE 100 6,674.48 -0.32%FTSE 250 15,494.97 -0.11%The FTSE 100 finished in negative territory for the first time in 10 trading sessions on Wednesday as traders took profits after the index hit a five-month high on the previous day.Concerns over the economic outlook in China and weakness in the heavyweight mining and banking sectors weighed on London's benchmark index today, which finished down 21.18 points at 6,674.48. The FTSE 100 was pulling back after hitting its highest closing levels since May 28th on Tuesday.The bullish mood was dampened today by concerns over the Chinese economy after the news that debt write-offs at China's biggest lenders had tripled in the first half. Meanwhile, the People's Bank of China refrained from adding liquidity to the market through new reverse repurchase operations which led to a sharp increase in the country's benchmark money-market rate.Chief Market Analyst Michael Hewson from CMC Markets said that the reports have prompted "concerns that a fiscal tightening could well see a slowdown in the recent recovery in the Chinese economy".However, he said: "In reality we have been due a pullback for some time now given the recent run up, and given the fact that a lot of this week's earnings reports have shown some worrying signs of weakness."Miners and banks fall, while RSA jumpsMining stocks including Antofagasta and Anglo American were out of favour on concerns over China in addition to gloomy results from US bellwether Caterpillar, which makes heavy machinery for the mining and ground-moving industries. The firm disappointed Wall Street forecasts with its full-year guidance owing to weak mining orders, saying that "significant risks and uncertainties" could temper global economic growth next year.Banks all over Europe were lower after the European Central Bank said it would start to review the balance sheets of 130 institutions across the continent. RBS, Barclays, Lloyds, HSBC and Standard Chartered were all registering losses in London.Insurance firm RSA was a high riser on speculation that the firm could be the target of a takeover bid. Reuters cited traders as touting Italian group Generali, Swiss firm Zurich Financial and UK peer Aviva as potential bidders.Chip designer ARM Holdings fell for the second straight day as investors gave a cool reaction to its third-quarter results. JPMorgan Cazenove said this morning that it sees "no reason to be building positions at this time and would take profits in the short term."A number of stocks were also trading in the red after going ex-dividend, including Smiths Group, BAE System, Rolls-Royce, John Menzies, Senior, William Hill, Rank Group, Barratt Developments and JD Wetherspoon.Banknote printer and ID services firm De La Rue was a big mover with shares sinking after the company warned that it would miss its full-year profit target by £10m owing to "challenging trading conditions".Drugs group GlaxoSmithKline beat earnings growth expectations in the third quarter by cutting back office and drug research and development costs were amplified by a lower tax rate. However, shares fell after revenue growth of 1% to £6.51bn missed forecacts.FTSE 100 - RisersRSA Insurance Group (RSA) 127.00p +2.50%Persimmon (PSN) 1,256.00p +2.36%United Utilities Group (UU.) 716.50p +1.63%International Consolidated Airlines Group SA (CDI) (IAG) 364.80p +1.62%ITV (ITV) 195.00p +1.51%Hargreaves Lansdown (HL.) 1,171.00p +1.47%Legal & General Group (LGEN) 213.00p +1.43%Babcock International Group (BAB) 1,260.00p +1.37%Travis Perkins (TPK) 1,805.00p +1.29%Shire Plc (SHP) 2,525.00p +1.28%FTSE 100 - FallersARM Holdings (ARM) 953.50p -5.03%Antofagasta (ANTO) 865.50p -4.26%Smiths Group (SMIN) 1,397.00p -3.99%Anglo American (AAL) 1,495.00p -3.92%Royal Bank of Scotland Group (RBS) 352.10p -2.73%GlaxoSmithKline (GSK) 1,570.50p -1.91%Sage Group (SGE) 327.00p -1.83%CRH (CRH) 1,517.00p -1.81%Barclays (BARC) 268.20p -1.61%Standard Chartered (STAN) 1,500.00p -1.45%FTSE 250 - RisersPace (PIC) 323.80p +11.66%Laird (LRD) 243.90p +8.06%IP Group (IPO) 149.00p +5.23%Home Retail Group (HOME) 192.10p +4.23%AL Noor Hospitals Group (ANH) 918.00p +3.73%Supergroup (SGP) 1,186.00p +3.31%Dixons Retail (DXNS) 48.20p +3.26%BBA Aviation (BBA) 336.60p +2.97%BTG (BTG) 407.90p +2.85%Kenmare Resources (KMR) 22.39p +2.85%FTSE 250 - FallersDe La Rue (DLAR) 885.50p -9.73%International Personal Finance (IPF) 623.00p -6.81%Telecity Group (TCY) 779.50p -5.74%Essar Energy (ESSR) 120.20p -5.43%Ferrexpo (FXPO) 184.70p -4.74%Evraz (EVR) 128.40p -4.32%Kazakhmys (KAZ) 251.40p -4.05%Centamin (DI) (CEY) 49.76p -4.03%Premier Oil (PMO) 328.50p -3.38%AZ Electronic Materials SA (DI) (AZEM) 286.90p -3.07%BC
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.